SIMILAR PATTERNS OF AMINO ACIDS FOR 5LW1_H_ADNH401

List of similar pattern of amino acids derived from ASSAM search

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click link on the last column to view superposed patterns of amino acids in NGL viewer)
(Note that only 3-12 residue patterns can be used for ASSAM searches)

Filter list by:

	Hit	Macromolecule/ Organism	Pfam	Res.	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1cm8	PHOSPHORYLATED MAP KINASE P38-GAMMA (Homo sapiens)	PF00069 (Pkinase)	5	VAL A 41 ALA A 54 MET A 109 MET A 112 LEU A 170	ANP A 400 (-4.1A) ANP A 400 (-3.3A) ANP A 400 (-4.6A) None ANP A 400 (-4.0A)	0.62A	5lw1H-1cm8A: 35.8	5lw1H-1cm8A: 42.50
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1ii0	ARSENICAL PUMP-DRIVING ATPASE (Escherichia coli)	PF02374 (ArsA_ATPase)	5	GLY A 51 VAL A 50 LEU A 288 VAL A 68 LEU A 71	None	1.02A	5lw1H-1ii0A: undetectable	5lw1H-1ii0A: 8.17
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1iir	GLYCOSYLTRANSFERASE GTFB (Amycolatopsis orientalis)	PF03033 (Glyco_transf_28)	5	GLY A 300 VAL A 302 ASN A 294 VAL A 293 LEU A 230	None	1.05A	5lw1H-1iirA: undetectable	5lw1H-1iirA: 11.70
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1jmz	AMINE DEHYDROGENASE (Pseudomonas putida)	PF09098 (Dehyd-heme_bind) PF09099 (Qn_am_d_aIII) PF09100 (Qn_am_d_aIV) PF14930 (Qn_am_d_aII)	5	GLY A 316 VAL A 319 ALA A 336 LEU A 334 VAL A 289	None	0.89A	5lw1H-1jmzA: undetectable	5lw1H-1jmzA: 11.62
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1k4q	GLUTATHIONE REDUCTASE (Homo sapiens)	PF02852 (Pyr_redox_dim) PF07992 (Pyr_redox_2)	5	GLY A 157 VAL A 332 ALA A 328 LEU A 153 LEU A 298	FAD A 499 (-3.4A) None None None None	0.95A	5lw1H-1k4qA: undetectable	5lw1H-1k4qA: 12.78
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1l5j	ACONITATE HYDRATASE 2 (Escherichia coli)	PF00330 (Aconitase) PF06434 (Aconitase_2_N) PF11791 (Aconitase_B_N)	5	GLY A 275 VAL A 236 ALA A 234 LEU A 272 VAL A 316	None	1.06A	5lw1H-1l5jA: undetectable	5lw1H-1l5jA: 6.69
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1nex	CENTROMERE DNA-BINDING PROTEIN COMPLEX CBF3 SUBUNIT D (Saccharomyces cerevisiae)	PF01466 (Skp1) PF03931 (Skp1_POZ)	5	VAL A 18 ALA A 23 LEU A 29 VAL A 79 LEU A 87	None	0.87A	5lw1H-1nexA: undetectable	5lw1H-1nexA: 20.71
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1oru	YUAD PROTEIN (Bacillus subtilis)	no annotation	5	GLY A 34 VAL A 164 ALA A 118 ASN A 94 VAL A 95	None	1.06A	5lw1H-1oruA: undetectable	5lw1H-1oruA: 16.75
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1s9i	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	5	GLY A 79 VAL A 86 ALA A 99 MET A 147 LEU A 201	ATP A 535 ( 3.9A) ATP A 535 (-4.1A) ATP A 535 (-3.6A) ATP A 535 ( 3.4A) ATP A 535 (-4.8A)	1.01A	5lw1H-1s9iA: 11.6	5lw1H-1s9iA: 15.03
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1s9i	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	5	GLY A 79 VAL A 86 ALA A 99 MET A 147 MET A 150	ATP A 535 ( 3.9A) ATP A 535 (-4.1A) ATP A 535 (-3.6A) ATP A 535 ( 3.4A) None	0.57A	5lw1H-1s9iA: 11.6	5lw1H-1s9iA: 15.03
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1upi	DTDP-4-DEHYDRORHAMNO SE 3,5-EPIMERASE (Mycobacterium tuberculosis)	PF00908 (dTDP_sugar_isom)	5	GLY A 96 ALA A 118 LEU A 61 VAL A 180 LEU A 186	None None CME A 147 ( 4.9A) None None	1.07A	5lw1H-1upiA: undetectable	5lw1H-1upiA: 19.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2b1p	MITOGEN-ACTIVATED PROTEIN KINASE 10 (Homo sapiens)	PF00069 (Pkinase)	7	GLY A 71 ALA A 91 LEU A 148 MET A 149 ASN A 152 VAL A 196 LEU A 206	AIZ A 501 ( 4.0A) AIZ A 501 (-3.4A) AIZ A 501 ( 4.7A) None AIZ A 501 (-3.6A) None AIZ A 501 (-4.0A)	0.91A	5lw1H-2b1pA: 43.9	5lw1H-2b1pA: 93.65
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2b1p	MITOGEN-ACTIVATED PROTEIN KINASE 10 (Homo sapiens)	PF00069 (Pkinase)	7	VAL A 78 ALA A 91 LEU A 148 MET A 149 ASN A 152 VAL A 196 LEU A 206	AIZ A 501 ( 4.7A) AIZ A 501 (-3.4A) AIZ A 501 ( 4.7A) None AIZ A 501 (-3.6A) None AIZ A 501 (-4.0A)	0.49A	5lw1H-2b1pA: 43.9	5lw1H-2b1pA: 93.65
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2b1p	MITOGEN-ACTIVATED PROTEIN KINASE 10 (Homo sapiens)	PF00069 (Pkinase)	7	VAL A 78 ALA A 91 MET A 146 LEU A 148 ASN A 152 VAL A 196 LEU A 206	AIZ A 501 ( 4.7A) AIZ A 501 (-3.4A) AIZ A 501 (-3.8A) AIZ A 501 ( 4.7A) AIZ A 501 (-3.6A) None AIZ A 501 (-4.0A)	0.73A	5lw1H-2b1pA: 43.9	5lw1H-2b1pA: 93.65
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2f9g	MITOGEN-ACTIVATED PROTEIN KINASE FUS3 (Saccharomyces cerevisiae)	PF00069 (Pkinase)	5	GLY A 20 VAL A 27 ALA A 40 LEU A 95 MET A 96	ADP A 500 ( 4.1A) ADP A 500 (-4.3A) ADP A 500 ( 3.7A) ADP A 500 ( 4.9A) None	0.54A	5lw1H-2f9gA: 24.7	5lw1H-2f9gA: 13.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2h34	SERINE/THREONINE-PRO TEIN KINASE PKNE (Mycobacterium tuberculosis)	PF00069 (Pkinase)	5	GLY A 23 VAL A 30 ALA A 43 MET A 93 LEU A 95	None	0.70A	5lw1H-2h34A: 19.5	5lw1H-2h34A: 16.50
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2hz0	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	GLY A 249 VAL A 256 ALA A 269 MET A 318 ASN A 322	None GIN A 600 ( 4.7A) GIN A 600 (-3.1A) None None	0.59A	5lw1H-2hz0A: 20.6	5lw1H-2hz0A: 15.13
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2ixc	DTDP-4-DEHYDRORHAMNO SE 3,5-EPIMERASE RMLC (Mycobacterium tuberculosis)	PF00908 (dTDP_sugar_isom)	5	GLY A 96 ALA A 118 LEU A 61 VAL A 180 LEU A 186	None	0.91A	5lw1H-2ixcA: undetectable	5lw1H-2ixcA: 18.91
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2j0j	FOCAL ADHESION KINASE 1 (Gallus gallus)	PF00373 (FERM_M) PF07714 (Pkinase_Tyr)	5	GLY A 429 VAL A 436 ALA A 452 MET A 499 LEU A 501	4ST A1687 (-3.1A) 4ST A1687 ( 4.8A) 4ST A1687 (-3.3A) 4ST A1687 ( 3.9A) 4ST A1687 (-4.3A)	0.43A	5lw1H-2j0jA: 20.5	5lw1H-2j0jA: 8.72
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2jc6	CALCIUM/CALMODULIN-D EPENDENT PROTEIN KINASE TYPE 1D (Homo sapiens)	PF00069 (Pkinase)	5	GLY A 30 VAL A 37 ALA A 50 MET A 98 LEU A 100	QPP A1314 ( 3.7A) QPP A1314 ( 4.6A) QPP A1314 ( 3.7A) QPP A1314 ( 4.1A) QPP A1314 (-4.5A)	0.70A	5lw1H-2jc6A: 19.7	5lw1H-2jc6A: 13.17
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2jkm	FOCAL ADHESION KINASE 1 (Gallus gallus)	PF07714 (Pkinase_Tyr)	5	GLY A 429 VAL A 436 ALA A 452 MET A 499 LEU A 501	BII A1687 ( 3.8A) BII A1687 ( 4.7A) BII A1687 (-3.5A) BII A1687 (-4.1A) BII A1687 (-4.4A)	0.59A	5lw1H-2jkmA: 20.2	5lw1H-2jkmA: 12.68
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2phk	PHOSPHORYLASE KINASE (Oryctolagus cuniculus)	PF00069 (Pkinase)	5	GLY A 26 VAL A 33 ALA A 46 LEU A 105 MET A 106	ATP A 381 (-3.5A) ATP A 381 (-4.1A) ATP A 381 (-3.5A) None None	0.48A	5lw1H-2phkA: 23.3	5lw1H-2phkA: 13.43
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2qkw	PROTEIN KINASE (Solanum pimpinellifolium)	PF07714 (Pkinase_Tyr)	5	GLY B 48 VAL B 55 ALA B 67 MET B 117 ASN B 121	None	0.40A	5lw1H-2qkwB: 20.9	5lw1H-2qkwB: 13.56
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2r4b	RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4 (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	GLY A 725 VAL A 732 ALA A 749 LEU A 798 MET A 799	None GW7 A 1 ( 4.8A) GW7 A 1 (-3.3A) GW7 A 1 (-4.5A) None	0.61A	5lw1H-2r4bA: 19.9	5lw1H-2r4bA: 13.31
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2v55	RHO-ASSOCIATED PROTEIN KINASE 1 (Homo sapiens)	PF00069 (Pkinase)	5	GLY A 83 VAL A 90 ALA A 103 MET A 153 MET A 156	ANP A1480 ( 4.3A) None ANP A1480 ( 3.9A) ANP A1480 (-4.1A) None	0.52A	5lw1H-2v55A: 22.7	5lw1H-2v55A: 9.85
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2w3y	VIRULENCE FACTOR (Pectobacterium carotovorum)	no annotation	5	GLY A 35 VAL A 42 ALA A 171 ASN A 79 VAL A 78	None	1.03A	5lw1H-2w3yA: undetectable	5lw1H-2w3yA: 13.78
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2xk9	CHECKPOINT KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	5	GLY A 227 VAL A 234 ALA A 247 LEU A 303 MET A 304	XK9 A1511 ( 4.5A) XK9 A1511 (-4.8A) XK9 A1511 ( 4.1A) XK9 A1511 (-4.1A) None	0.53A	5lw1H-2xk9A: 14.9	5lw1H-2xk9A: 14.78
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2y7j	PHOSPHORYLASE B KINASE GAMMA CATALYTIC CHAIN, TESTIS/LIVER ISOFORM (Homo sapiens)	PF00069 (Pkinase)	5	GLY A 31 VAL A 38 ALA A 51 LEU A 109 MET A 110	B49 A1294 (-4.0A) None B49 A1294 (-3.2A) B49 A1294 ( 4.7A) None	0.43A	5lw1H-2y7jA: 12.5	5lw1H-2y7jA: 13.89
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2yfk	ASPARTATE/ORNITHINE CARBAMOYLTRANSFERASE (Enterococcus faecalis)	PF00185 (OTCace) PF02729 (OTCace_N)	5	GLY A 63 ALA A 81 MET A 371 VAL A 157 LEU A 159	None	1.00A	5lw1H-2yfkA: undetectable	5lw1H-2yfkA: 10.02
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2z8c	INSULIN RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	GLY A1003 VAL A1010 ALA A1028 MET A1076 LEU A1078 MET A1079	S91 A 1 ( 3.9A) S91 A 1 ( 4.9A) S91 A 1 (-3.2A) S91 A 1 ( 4.9A) S91 A 1 (-4.7A) None	0.62A	5lw1H-2z8cA: 22.6	5lw1H-2z8cA: 16.81
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3coi	MITOGEN-ACTIVATED PROTEIN KINASE 13 (Homo sapiens)	PF00069 (Pkinase)	6	GLY A 32 VAL A 39 ALA A 52 MET A 107 MET A 110 LEU A 167	None	0.78A	5lw1H-3coiA: 36.1	5lw1H-3coiA: 11.93
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3e7o	MITOGEN-ACTIVATED PROTEIN KINASE 9 (Homo sapiens)	PF00069 (Pkinase)	8	GLY A 33 VAL A 40 ALA A 53 MET A 108 LEU A 110 MET A 111 ASN A 114 VAL A 158	35F A 1 ( 4.8A) 35F A 1 ( 4.8A) 35F A 1 (-3.6A) 35F A 1 ( 3.9A) 35F A 1 (-4.5A) None None None	0.73A	5lw1H-3e7oA: 43.5	5lw1H-3e7oA: 70.51
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3e7o	MITOGEN-ACTIVATED PROTEIN KINASE 9 (Homo sapiens)	PF00069 (Pkinase)	8	GLY A 33 VAL A 40 ALA A 53 MET A 108 LEU A 110 MET A 111 VAL A 158 LEU A 168	35F A 1 ( 4.8A) 35F A 1 ( 4.8A) 35F A 1 (-3.6A) 35F A 1 ( 3.9A) 35F A 1 (-4.5A) None None 35F A 1 (-4.5A)	0.48A	5lw1H-3e7oA: 43.5	5lw1H-3e7oA: 70.51
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3fme	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6 (Homo sapiens)	PF00069 (Pkinase)	6	GLY A 60 VAL A 67 ALA A 80 MET A 129 LEU A 131 MET A 132	STU A 1 (-3.5A) None STU A 1 (-3.4A) STU A 1 ( 3.8A) STU A 1 (-4.6A) None	0.52A	5lw1H-3fmeA: 20.8	5lw1H-3fmeA: 12.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3g2f	BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-2 (Homo sapiens)	PF00069 (Pkinase)	5	GLY A 210 VAL A 217 ALA A 228 MET A 279 LEU A 340	ADP A 900 (-3.4A) ADP A 900 (-4.3A) ADP A 900 (-3.4A) ADP A 900 (-3.6A) ADP A 900 (-4.6A)	0.92A	5lw1H-3g2fA: 21.5	5lw1H-3g2fA: 15.67
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3gp0	MITOGEN-ACTIVATED PROTEIN KINASE 11 (Homo sapiens)	PF00069 (Pkinase)	6	GLY A 31 VAL A 38 ALA A 51 LEU A 108 MET A 109 LEU A 167	None NIL A 1 ( 4.7A) NIL A 1 (-3.7A) NIL A 1 ( 4.4A) None NIL A 1 (-4.0A)	0.79A	5lw1H-3gp0A: 37.5	5lw1H-3gp0A: 14.49
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3gz7	PUTATIVE ANTIBIOTIC BIOSYNTHESIS MONOOXYGENASE (Bordetella bronchiseptica)	PF03992 (ABM)	5	GLY A 21 VAL A 79 LEU A 28 VAL A 38 LEU A 52	None None None None CIT A 97 (-4.5A)	1.04A	5lw1H-3gz7A: undetectable	5lw1H-3gz7A: 21.37
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3h4i	GLYCOSYLTRANSFERASE GTFA, GLYCOSYLTRANSFERASE (Actinoplanes teichomyceticus; Amycolatopsis orientalis)	PF03033 (Glyco_transf_28) PF04101 (Glyco_tran_28_C)	5	GLY A 283 VAL A 285 ASN A 277 VAL A 276 LEU A 213	None None None U2F A 547 (-4.0A) None	0.97A	5lw1H-3h4iA: undetectable	5lw1H-3h4iA: 10.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3hko	CALCIUM/CALMODULIN-D EPENDENT PROTEIN KINASE WITH A KINASE DOMAIN AND 2 CALMODULIN-LIKE EF HANDS (Cryptosporidium parvum)	PF00069 (Pkinase)	5	GLY A 17 VAL A 24 ALA A 37 LEU A 91 VAL A 194	ANP A 329 (-3.5A) ANP A 329 (-4.4A) ANP A 329 ( 3.7A) ANP A 329 ( 4.7A) None	1.01A	5lw1H-3hkoA: 23.4	5lw1H-3hkoA: 13.04
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3hko	CALCIUM/CALMODULIN-D EPENDENT PROTEIN KINASE WITH A KINASE DOMAIN AND 2 CALMODULIN-LIKE EF HANDS (Cryptosporidium parvum)	PF00069 (Pkinase)	5	GLY A 17 VAL A 24 ALA A 37 MET A 89 LEU A 91	ANP A 329 (-3.5A) ANP A 329 (-4.4A) ANP A 329 ( 3.7A) ANP A 329 (-3.7A) ANP A 329 ( 4.7A)	0.32A	5lw1H-3hkoA: 23.4	5lw1H-3hkoA: 13.04
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3i6u	SERINE/THREONINE-PRO TEIN KINASE CHK2 (Homo sapiens)	PF00069 (Pkinase) PF00498 (FHA)	5	GLY A 227 VAL A 234 ALA A 247 LEU A 303 MET A 304	None	0.75A	5lw1H-3i6uA: 21.8	5lw1H-3i6uA: 12.65
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3lj0	SERINE/THREONINE-PRO TEIN KINASE/ENDORIBONUCLE ASE IRE1 (Saccharomyces cerevisiae)	PF00069 (Pkinase) PF06479 (Ribonuc_2-5A)	5	GLY A 681 VAL A 689 ALA A 700 LEU A 747 ASN A 751	ADP A2101 (-3.6A) ADP A2101 (-4.5A) ADP A2101 (-3.5A) None ADP A2101 (-3.7A)	0.61A	5lw1H-3lj0A: 21.3	5lw1H-3lj0A: 11.55
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3lw0	INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	GLY A1006 VAL A1013 ALA A1031 MET A1079 LEU A1081 MET A1082	None None None CCX A 1 ( 3.9A) None None	0.69A	5lw1H-3lw0A: 21.7	5lw1H-3lw0A: 13.29
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3lzb	EPIDERMAL GROWTH FACTOR RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	GLY A 695 VAL A 702 ALA A 719 LEU A 768 LEU A 820	ITI A 1 ( 4.8A) ITI A 1 (-4.8A) ITI A 1 (-2.9A) ITI A 1 (-4.8A) ITI A 1 (-4.6A)	0.92A	5lw1H-3lzbA: 19.3	5lw1H-3lzbA: 12.59
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3nyo	G PROTEIN-COUPLED RECEPTOR KINASE 6 (Homo sapiens)	PF00069 (Pkinase) PF00615 (RGS)	5	GLY A 193 VAL A 200 ALA A 213 LEU A 265 MET A 266	AMP A 577 ( 3.7A) AMP A 577 (-4.3A) AMP A 577 (-3.4A) AMP A 577 ( 4.9A) None	0.39A	5lw1H-3nyoA: 24.7	5lw1H-3nyoA: 9.56
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3o0h	GLUTATHIONE REDUCTASE (Bartonella henselae)	PF02852 (Pyr_redox_dim) PF07992 (Pyr_redox_2)	5	GLY A 142 VAL A 306 ALA A 302 LEU A 138 LEU A 272	FAD A 500 (-3.2A) None None None FAD A 500 ( 4.5A)	0.99A	5lw1H-3o0hA: undetectable	5lw1H-3o0hA: 11.16
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3oht	P38A (Salmo salar)	PF00069 (Pkinase)	5	GLY A 32 VAL A 39 ALA A 52 LEU A 109 LEU A 168	1N1 A1000 (-3.4A) 1N1 A1000 (-4.6A) 1N1 A1000 (-3.7A) 1N1 A1000 (-4.7A) 1N1 A1000 ( 3.7A)	0.79A	5lw1H-3ohtA: 30.0	5lw1H-3ohtA: 35.25
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3oht	P38A (Salmo salar)	PF00069 (Pkinase)	5	GLY A 32 VAL A 39 ALA A 52 LEU A 109 MET A 110	1N1 A1000 (-3.4A) 1N1 A1000 (-4.6A) 1N1 A1000 (-3.7A) 1N1 A1000 (-4.7A) None	0.58A	5lw1H-3ohtA: 30.0	5lw1H-3ohtA: 35.25
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3pp0	RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	GLY A 727 VAL A 734 ALA A 751 LEU A 800 MET A 801	None 03Q A 1 (-4.5A) 03Q A 1 (-3.1A) 03Q A 1 (-4.6A) None	0.58A	5lw1H-3pp0A: 20.7	5lw1H-3pp0A: 14.34
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3rez	PLATELET GLYCOPROTEIN IB BETA CHAIN, PLATELET GLYCOPROTEIN IX (Homo sapiens)	PF01462 (LRRNT) PF01463 (LRRCT)	5	GLY A 59 ALA A 56 LEU A 32 VAL A 42 LEU A 72	None	0.97A	5lw1H-3rezA: undetectable	5lw1H-3rezA: 17.16
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3she	MAP KINASE-ACTIVATED PROTEIN KINASE 3 (Homo sapiens)	PF00069 (Pkinase)	5	GLY A 51 VAL A 58 ALA A 71 MET A 118 MET A 121	I85 A 350 (-3.5A) I85 A 350 (-4.9A) I85 A 350 (-3.3A) I85 A 350 ( 3.9A) None	0.51A	5lw1H-3sheA: 18.3	5lw1H-3sheA: 12.75
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3vn9	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6 (Homo sapiens)	PF00069 (Pkinase)	6	GLY A 60 VAL A 67 ALA A 80 MET A 129 LEU A 131 MET A 132	ANK A 401 (-3.4A) ANK A 401 (-4.3A) ANK A 401 (-3.0A) ANK A 401 (-3.7A) None None	0.60A	5lw1H-3vn9A: 21.1	5lw1H-3vn9A: 13.82
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3vn9	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6 (Homo sapiens)	PF00069 (Pkinase)	5	GLY A 60 VAL A 67 ALA A 80 MET A 129 LEU A 186	ANK A 401 (-3.4A) ANK A 401 (-4.3A) ANK A 401 (-3.0A) ANK A 401 (-3.7A) ANK A 401 ( 4.9A)	1.03A	5lw1H-3vn9A: 21.1	5lw1H-3vn9A: 13.82
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3wcz	ALDO-KETO REDUCTASE 2E (Bombyx mori)	PF00248 (Aldo_ket_red)	5	GLY A 67 VAL A 41 ALA A 44 VAL A 77 LEU A 82	None	1.05A	5lw1H-3wczA: undetectable	5lw1H-3wczA: 14.49
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	PF00069 (Pkinase)	5	GLY A 76 VAL A 83 ALA A 96 MET A 144 MET A 147	ANP A 401 ( 3.7A) ANP A 401 ( 4.3A) ANP A 401 (-3.2A) CHU A 403 (-3.8A) None	0.30A	5lw1H-3wigA: 21.4	5lw1H-3wigA: 15.28
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4b99	MITOGEN-ACTIVATED PROTEIN KINASE 7 (Homo sapiens)	PF00069 (Pkinase)	5	GLY A 62 VAL A 69 ALA A 82 LEU A 139 MET A 140	R4L A1394 (-3.6A) R4L A1394 (-4.0A) R4L A1394 ( 3.7A) R4L A1394 ( 4.9A) None	0.42A	5lw1H-4b99A: 35.9	5lw1H-4b99A: 11.34
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4btm	TAU-TUBULIN KINASE 1 (Homo sapiens)	PF00069 (Pkinase)	5	GLY A 65 ALA A 85 LEU A 133 ASN A 137 LEU A 199	F8E A1340 ( 4.3A) F8E A1340 (-3.5A) F8E A1340 (-4.4A) F8E A1340 ( 4.5A) F8E A1340 (-3.8A)	0.87A	5lw1H-4btmA: 14.0	5lw1H-4btmA: 11.47
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4btm	TAU-TUBULIN KINASE 1 (Homo sapiens)	PF00069 (Pkinase)	5	GLY A 65 ALA A 85 MET A 131 LEU A 133 ASN A 137	F8E A1340 ( 4.3A) F8E A1340 (-3.5A) F8E A1340 (-4.2A) F8E A1340 (-4.4A) F8E A1340 ( 4.5A)	0.67A	5lw1H-4btmA: 14.0	5lw1H-4btmA: 11.47
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4drr	OUTER CAPSID PROTEIN VP4 (Rotavirus sp.)	no annotation	5	GLY A 90 VAL A 106 ALA A 104 VAL A 126 LEU A 128	None	0.86A	5lw1H-4drrA: undetectable	5lw1H-4drrA: 17.79
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4fg8	CALCIUM/CALMODULIN-D EPENDENT PROTEIN KINASE TYPE 1 (Homo sapiens)	PF00069 (Pkinase)	5	GLY A 27 VAL A 34 ALA A 47 MET A 95 LEU A 97	ATP A 401 ( 3.7A) ATP A 401 (-4.1A) ATP A 401 (-3.6A) ATP A 401 ( 4.3A) ATP A 401 ( 4.8A)	0.53A	5lw1H-4fg8A: 18.0	5lw1H-4fg8A: 13.97
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4fod	ALK TYROSINE KINASE RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	GLY A1123 VAL A1130 ALA A1148 LEU A1198 MET A1199	0UV A1501 ( 4.3A) 0UV A1501 (-4.5A) 0UV A1501 (-3.4A) 0UV A1501 ( 4.8A) None	0.61A	5lw1H-4fodA: 20.2	5lw1H-4fodA: 16.02
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4g3f	NF-KAPPA-BETA-INDUCI NG KINASE (Mus musculus)	PF00069 (Pkinase)	5	GLY A 409 VAL A 416 ALA A 429 MET A 471 LEU A 473	0WB A 701 ( 4.4A) 0WB A 701 (-4.4A) 0WB A 701 (-3.3A) 0WB A 701 (-3.9A) 0WB A 701 (-4.3A)	0.60A	5lw1H-4g3fA: 16.9	5lw1H-4g3fA: 13.25
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4g3f	NF-KAPPA-BETA-INDUCI NG KINASE (Mus musculus)	PF00069 (Pkinase)	5	GLY A 409 VAL A 416 ALA A 429 MET A 471 LEU A 524	0WB A 701 ( 4.4A) 0WB A 701 (-4.4A) 0WB A 701 (-3.3A) 0WB A 701 (-3.9A) 0WB A 701 (-4.3A)	0.97A	5lw1H-4g3fA: 16.9	5lw1H-4g3fA: 13.25
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4idt	MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 14 (Homo sapiens)	PF00069 (Pkinase)	5	GLY A 407 VAL A 414 ALA A 427 MET A 469 LEU A 471	T28 A 701 ( 3.6A) T28 A 701 (-4.7A) T28 A 701 (-3.0A) T28 A 701 (-2.6A) T28 A 701 ( 4.8A)	0.51A	5lw1H-4idtA: 16.9	5lw1H-4idtA: 10.92
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4j57	THIOREDOXIN REDUCTASE 2 (Plasmodium falciparum)	PF02852 (Pyr_redox_dim) PF07992 (Pyr_redox_2)	5	GLY A 193 VAL A 358 ALA A 354 LEU A 189 LEU A 323	FAD A 601 (-3.3A) None None None FAD A 601 (-4.9A)	0.98A	5lw1H-4j57A: undetectable	5lw1H-4j57A: 11.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4jrn	RHOPTRY KINASE FAMILY PROTEIN (Toxoplasma gondii)	PF14531 (Kinase-like)	5	GLY A 259 VAL A 266 ALA A 279 MET A 356 LEU A 416	ANP A 601 (-3.4A) ANP A 601 (-4.1A) ANP A 601 ( 3.9A) ANP A 601 (-3.3A) ANP A 601 ( 4.9A)	1.04A	5lw1H-4jrnA: 13.7	5lw1H-4jrnA: 12.83
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4mk0	BETA-ADRENERGIC RECEPTOR KINASE 1 (Homo sapiens)	PF00069 (Pkinase) PF00169 (PH) PF00615 (RGS)	5	GLY A 198 VAL A 205 ALA A 218 LEU A 273 MET A 274	29X A 702 ( 4.1A) 29X A 702 (-4.7A) 29X A 702 (-3.1A) 29X A 702 (-4.6A) None	0.83A	5lw1H-4mk0A: 23.7	5lw1H-4mk0A: 8.45
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4mvf	CALCIUM-DEPENDENT PROTEIN KINASE 2 (Plasmodium falciparum)	PF00069 (Pkinase) PF13499 (EF-hand_7)	5	GLY A 79 VAL A 86 ALA A 99 MET A 146 LEU A 148	STU A 601 (-3.6A) STU A 601 (-4.8A) STU A 601 (-3.3A) STU A 601 ( 4.3A) STU A 601 (-4.3A)	0.53A	5lw1H-4mvfA: 19.8	5lw1H-4mvfA: 9.49
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4nfn	TAU-TUBULIN KINASE 1 (Homo sapiens)	PF00069 (Pkinase)	5	ALA A 61 MET A 107 LEU A 109 ASN A 113 LEU A 175	2KC A 401 (-2.7A) 2KC A 401 (-4.1A) 2KC A 401 ( 4.7A) None 2KC A 401 ( 3.9A)	0.89A	5lw1H-4nfnA: 19.1	5lw1H-4nfnA: 11.73
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4nfn	TAU-TUBULIN KINASE 1 (Homo sapiens)	PF00069 (Pkinase)	5	GLY A 41 ALA A 61 MET A 107 LEU A 109 LEU A 175	2KC A 401 ( 3.2A) 2KC A 401 (-2.7A) 2KC A 401 (-4.1A) 2KC A 401 ( 4.7A) 2KC A 401 ( 3.9A)	0.99A	5lw1H-4nfnA: 19.1	5lw1H-4nfnA: 11.73
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4pwn	SERINE/THREONINE-PRO TEIN KINASE WNK1 (Homo sapiens)	PF00069 (Pkinase)	5	GLY A 228 VAL A 235 ALA A 248 LEU A 303 MET A 304	None	0.53A	5lw1H-4pwnA: 20.1	5lw1H-4pwnA: 14.44
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4q6l	PENICILLIN-BINDING PROTEIN ACTIVATOR LPOB (Salmonella enterica)	PF13036 (LpoB)	5	VAL A 87 MET A 191 LEU A 193 VAL A 104 LEU A 124	None	1.06A	5lw1H-4q6lA: undetectable	5lw1H-4q6lA: 23.48
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4qi3	CELLOBIOSE DEHYDROGENASE (Crassicarpon hotsonii)	PF16010 (CDH-cyt)	5	GLY A 149 ALA A 144 ASN A 18 VAL A 37 LEU A 39	MG A 407 (-3.8A) None None None None	1.01A	5lw1H-4qi3A: undetectable	5lw1H-4qi3A: 22.05
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4qny	MITOGEN ACTIVATED PROTEIN KINASE, PUTATIVE (Leishmania donovani)	PF00069 (Pkinase)	5	GLY A 28 VAL A 35 ALA A 49 MET A 104 MET A 107	ANP A 402 ( 3.7A) ANP A 402 (-4.3A) ANP A 402 (-3.3A) ANP A 402 (-4.4A) None	0.48A	5lw1H-4qnyA: 35.3	5lw1H-4qnyA: 14.04
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4qtb	MITOGEN-ACTIVATED PROTEIN KINASE 3 (Homo sapiens)	PF00069 (Pkinase)	5	GLY A 49 VAL A 56 ALA A 69 LEU A 124 MET A 125	None None 38Z A 418 (-3.4A) 38Z A 418 ( 4.8A) None	0.41A	5lw1H-4qtbA: 37.8	5lw1H-4qtbA: 10.46
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4tyh	MITOGEN-ACTIVATED PROTEIN KINASE 14 (Mus musculus)	PF00069 (Pkinase)	5	GLY B 31 ALA B 51 LEU B 108 MET B 109 LEU B 167	None 39G B 401 (-3.5A) 39G B 401 ( 4.9A) 39G B 401 (-4.8A) 39G B 401 (-3.6A)	0.80A	5lw1H-4tyhB: 15.5	5lw1H-4tyhB: 11.21
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4tyh	MITOGEN-ACTIVATED PROTEIN KINASE 14 (Mus musculus)	PF00069 (Pkinase)	5	GLY B 31 VAL B 38 ALA B 51 LEU B 108 MET B 109	None None 39G B 401 (-3.5A) 39G B 401 ( 4.9A) 39G B 401 (-4.8A)	0.77A	5lw1H-4tyhB: 15.5	5lw1H-4tyhB: 11.21
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4u6d	CONSERVED HYPOTHETICAL PERIPLASMIC PROTEIN (Zobellia galactanivorans)	no annotation	5	GLY A 283 VAL A 299 ALA A 297 LEU A 288 VAL A 279	None	1.08A	5lw1H-4u6dA: undetectable	5lw1H-4u6dA: 12.40
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4wbo	RHODOPSIN KINASE (Bos taurus)	PF00069 (Pkinase) PF00615 (RGS)	5	GLY A 194 VAL A 201 ALA A 214 MET A 264 MET A 267	None None ANW A 601 (-3.4A) ANW A 601 (-3.2A) None	0.45A	5lw1H-4wboA: 18.3	5lw1H-4wboA: 10.70
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4xrl	MITOGEN-ACTIVATED PROTEIN KINASE 1 (Rattus norvegicus)	PF00069 (Pkinase)	5	GLY A 30 VAL A 37 ALA A 50 LEU A 105 MET A 106	None None 42A A 402 (-3.2A) 42A A 402 ( 4.9A) None	0.58A	5lw1H-4xrlA: 37.2	5lw1H-4xrlA: 10.94
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5awm	STRESS-ACTIVATED PROTEIN KINASE JNK (Drosophila melanogaster)	PF00069 (Pkinase)	7	GLY A 31 ALA A 51 MET A 106 LEU A 108 MET A 109 VAL A 156 LEU A 166	ANP A 401 (-3.3A) ANP A 401 (-3.5A) ANP A 401 (-3.8A) ANP A 401 ( 4.8A) None None ANP A 401 ( 4.5A)	0.71A	5lw1H-5awmA: 44.0	5lw1H-5awmA: 64.44
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5awm	STRESS-ACTIVATED PROTEIN KINASE JNK (Drosophila melanogaster)	PF00069 (Pkinase)	8	VAL A 38 ALA A 51 MET A 106 LEU A 108 MET A 109 ASN A 112 VAL A 156 LEU A 166	ANP A 401 (-4.5A) ANP A 401 (-3.5A) ANP A 401 (-3.8A) ANP A 401 ( 4.8A) None ANP A 401 (-3.9A) None ANP A 401 ( 4.5A)	0.45A	5lw1H-5awmA: 44.0	5lw1H-5awmA: 64.44
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5b4s	CHITOSANASE (Mitsuaria chitosanitabida)	PF13647 (Glyco_hydro_80)	5	GLY A 112 VAL A 115 ALA A 153 LEU A 154 LEU A 98	None	1.08A	5lw1H-5b4sA: undetectable	5lw1H-5b4sA: 15.36
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5dbx	STE20/SPS1-RELATED PROLINE-ALANINE-RICH PROTEIN KINASE (Mus musculus)	PF00069 (Pkinase)	5	GLY A 82 VAL A 89 ALA A 102 MET A 150 LEU A 152	ANP A 401 ( 3.9A) ANP A 401 (-4.0A) ANP A 401 ( 4.0A) ANP A 401 (-4.0A) None	0.42A	5lw1H-5dbxA: 18.8	5lw1H-5dbxA: 14.15
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5j9z	EPIDERMAL GROWTH FACTOR RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	GLY A 719 VAL A 726 ALA A 743 LEU A 792 MET A 793	6HJ A1101 ( 4.2A) 6HJ A1101 ( 4.7A) 6HJ A1101 (-3.1A) 6HJ A1101 ( 4.9A) None	0.66A	5lw1H-5j9zA: 20.2	5lw1H-5j9zA: 12.42
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5j9z	EPIDERMAL GROWTH FACTOR RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	5	GLY A 719 VAL A 726 ALA A 743 MET A 790 LEU A 792	6HJ A1101 ( 4.2A) 6HJ A1101 ( 4.7A) 6HJ A1101 (-3.1A) 6HJ A1101 (-3.4A) 6HJ A1101 ( 4.9A)	0.77A	5lw1H-5j9zA: 20.2	5lw1H-5j9zA: 12.42
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5jzn	SERINE/THREONINE-PRO TEIN KINASE DCLK1 (Homo sapiens)	PF00069 (Pkinase)	5	GLY A 397 VAL A 404 ALA A 417 MET A 465 LEU A 467	GUI A 701 ( 3.8A) GUI A 701 (-4.4A) GUI A 701 ( 3.9A) GUI A 701 ( 4.1A) GUI A 701 ( 4.7A)	0.66A	5lw1H-5jznA: 19.6	5lw1H-5jznA: 14.13
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5lxd	DUAL SPECIFICITY TYROSINE-PHOSPHORYLA TION-REGULATED KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	5	GLY A 156 VAL A 163 ALA A 176 LEU A 230 ASN A 234	7A7 A 501 (-3.2A) 7A7 A 501 (-4.4A) 7A7 A 501 (-3.5A) None None	0.74A	5lw1H-5lxdA: 22.3	5lw1H-5lxdA: 13.64
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5o2c	SERINE/THREONINE-PRO TEIN KINASE WNK3 (Homo sapiens)	PF00069 (Pkinase) PF12202 (OSR1_C)	5	GLY A 154 VAL A 161 ALA A 174 LEU A 229 MET A 230	None None GOL A 604 ( 3.8A) GOL A 604 ( 4.8A) None	0.42A	5lw1H-5o2cA: 21.2	5lw1H-5o2cA: 11.35
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5tur	SERINE/THREONINE-PRO TEIN KINASE PIM-1 (Homo sapiens)	no annotation	5	GLY A 45 VAL A 52 ALA A 65 VAL A 126 LEU A 174	None 7LK A 401 (-4.9A) 7LK A 401 (-3.3A) None 7LK A 401 (-4.8A)	1.02A	5lw1H-5turA: 21.9	5lw1H-5turA: 13.20
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5u7q	RHO-ASSOCIATED PROTEIN KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	5	GLY A 99 VAL A 106 ALA A 119 MET A 169 MET A 172	None	0.42A	5lw1H-5u7qA: 23.5	5lw1H-5u7qA: 10.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5uuu	BETA-ADRENERGIC RECEPTOR KINASE 1 (Homo sapiens)	PF00069 (Pkinase) PF00615 (RGS)	5	GLY A 198 VAL A 205 ALA A 218 LEU A 273 MET A 274	QRW A 601 ( 4.5A) QRW A 601 (-4.7A) QRW A 601 (-3.4A) None MES A 604 (-3.9A)	0.69A	5lw1H-5uuuA: 23.4	5lw1H-5uuuA: 10.42
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5wnm	RECEPTOR-INTERACTING SERINE/THREONINE-PRO TEIN KINASE 4 (Mus musculus)	no annotation	5	GLY A 29 VAL A 36 ALA A 49 MET A 96 MET A 99	VX6 A 402 ( 4.2A) VX6 A 402 (-4.6A) VX6 A 402 (-3.2A) VX6 A 402 (-3.7A) None	0.55A	5lw1H-5wnmA: 21.7	5lw1H-5wnmA: 21.28
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5x1y	MERCURIC REDUCTASE (Lysinibacillus sphaericus)	no annotation	5	GLY B 220 VAL B 388 ALA B 384 LEU B 216 LEU B 354	FAD B 601 (-3.1A) None None None FAD B 601 (-4.6A)	0.97A	5lw1H-5x1yB: undetectable	5lw1H-5x1yB: 11.47
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6ao5	SERINE/THREONINE-PRO TEIN KINASE 3 (Homo sapiens)	no annotation	5	GLY A 34 VAL A 41 ALA A 54 MET A 99 LEU A 153	ANP A 501 ( 3.9A) ANP A 501 (-4.4A) ANP A 501 ( 3.7A) ANP A 501 (-2.5A) ANP A 501 (-4.6A)	1.08A	5lw1H-6ao5A: 19.8	5lw1H-6ao5A: 11.93
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6b4o	GLUTATHIONE REDUCTASE (Enterococcus faecalis)	no annotation	5	GLY A 139 VAL A 303 ALA A 299 LEU A 135 LEU A 269	FAD A 501 (-3.3A) None None None None	0.97A	5lw1H-6b4oA: undetectable	5lw1H-6b4oA: 12.85
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6b7p	SDED (Legionella pneumophila)	no annotation	5	GLY A 270 VAL A 269 MET A 230 ASN A 273 VAL A 274	None	1.05A	5lw1H-6b7pA: undetectable	5lw1H-6b7pA: 23.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6c7y	TYROSINE-PROTEIN KINASE JAK1 (Homo sapiens)	no annotation	5	GLY A 882 VAL A 889 ALA A 906 MET A 956 LEU A1010	ADP A1201 (-3.5A) ADP A1201 (-4.3A) ADP A1201 (-3.4A) ADP A1201 (-4.2A) ADP A1201 (-4.5A)	0.96A	5lw1H-6c7yA: 21.0	5lw1H-6c7yA: 22.09
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6cz4	PROTEIN-TYROSINE KINASE 6 (Homo sapiens)	no annotation	5	GLY A 198 VAL A 205 ALA A 217 LEU A 266 MET A 267	FKY A9001 ( 4.0A) FKY A9001 ( 4.6A) FKY A9001 (-3.3A) FKY A9001 (-4.4A) None	0.37A	5lw1H-6cz4A: 19.9	5lw1H-6cz4A: 24.49
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6fyl	DUAL SPECIFICITY PROTEIN KINASE CLK2 (Homo sapiens)	no annotation	5	GLY A 170 VAL A 177 ALA A 191 LEU A 245 LEU A 297	3NG A 501 (-3.5A) 3NG A 501 ( 4.4A) 3NG A 501 (-3.3A) 3NG A 501 ( 4.7A) None	1.07A	5lw1H-6fylA: 17.4	5lw1H-6fylA: undetectable

[["5LW1_H_ADNH401_1","1cm8","Homo sapiens","PHOSPHORYLATED MAP KINASE P38-GAMMA","PF00069(Pkinase)",5,"VAL A  41;ALA A  54;MET A 109;MET A 112;LEU A 170","ANP A 400 (-4.1A);ANP A 400 (-3.3A);ANP A 400 (-4.6A);None;ANP A 400 (-4.0A)","0.62A","5lw1H-1cm8A:35.8","5lw1H-1cm8A:42.50"],["5LW1_H_ADNH401_1","1ii0","Escherichia coli","ARSENICAL PUMP-DRIVING ATPASE","PF02374(ArsA_ATPase)",5,"GLY A  51;VAL A  50;LEU A 288;VAL A  68;LEU A  71","None","1.02A","5lw1H-1ii0A:undetectable","5lw1H-1ii0A:8.17"],["5LW1_H_ADNH401_1","1iir","Amycolatopsis orientalis","GLYCOSYLTRANSFERASE GTFB","PF03033(Glyco_transf_28)",5,"GLY A 300;VAL A 302;ASN A 294;VAL A 293;LEU A 230","None","1.05A","5lw1H-1iirA:undetectable","5lw1H-1iirA:11.70"],["5LW1_H_ADNH401_1","1jmz","Pseudomonas putida","AMINE DEHYDROGENASE","PF09098(Dehyd-heme_bind);PF09099(Qn_am_d_aIII);PF09100(Qn_am_d_aIV);PF14930(Qn_am_d_aII)",5,"GLY A 316;VAL A 319;ALA A 336;LEU A 334;VAL A 289","None","0.89A","5lw1H-1jmzA:undetectable","5lw1H-1jmzA:11.62"],["5LW1_H_ADNH401_1","1k4q","Homo sapiens","GLUTATHIONE REDUCTASE","PF02852(Pyr_redox_dim);PF07992(Pyr_redox_2)",5,"GLY A 157;VAL A 332;ALA A 328;LEU A 153;LEU A 298","FAD A 499 (-3.4A);None;None;None;None","0.95A","5lw1H-1k4qA:undetectable","5lw1H-1k4qA:12.78"],["5LW1_H_ADNH401_1","1l5j","Escherichia coli","ACONITATE HYDRATASE 2","PF00330(Aconitase);PF06434(Aconitase_2_N);PF11791(Aconitase_B_N)",5,"GLY A 275;VAL A 236;ALA A 234;LEU A 272;VAL A 316","None","1.06A","5lw1H-1l5jA:undetectable","5lw1H-1l5jA:6.69"],["5LW1_H_ADNH401_1","1nex","Saccharomyces cerevisiae","CENTROMERE DNA-BINDING PROTEIN COMPLEX CBF3 SUBUNIT D","PF01466(Skp1);PF03931(Skp1_POZ)",5,"VAL A  18;ALA A  23;LEU A  29;VAL A  79;LEU A  87","None","0.87A","5lw1H-1nexA:undetectable","5lw1H-1nexA:20.71"],["5LW1_H_ADNH401_1","1oru","Bacillus subtilis","YUAD PROTEIN","no annotation",5,"GLY A  34;VAL A 164;ALA A 118;ASN A  94;VAL A  95","None","1.06A","5lw1H-1oruA:undetectable","5lw1H-1oruA:16.75"],["5LW1_H_ADNH401_1","1s9i","Homo sapiens","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2","PF00069(Pkinase)",5,"GLY A  79;VAL A  86;ALA A  99;MET A 147;LEU A 201","ATP A 535 ( 3.9A);ATP A 535 (-4.1A);ATP A 535 (-3.6A);ATP A 535 ( 3.4A);ATP A 535 (-4.8A)","1.01A","5lw1H-1s9iA:11.6","5lw1H-1s9iA:15.03"],["5LW1_H_ADNH401_1","1s9i","Homo sapiens","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2","PF00069(Pkinase)",5,"GLY A  79;VAL A  86;ALA A  99;MET A 147;MET A 150","ATP A 535 ( 3.9A);ATP A 535 (-4.1A);ATP A 535 (-3.6A);ATP A 535 ( 3.4A);None","0.57A","5lw1H-1s9iA:11.6","5lw1H-1s9iA:15.03"],["5LW1_H_ADNH401_1","1upi","Mycobacterium tuberculosis","DTDP-4-DEHYDRORHAMNOSE 3,5-EPIMERASE","PF00908(dTDP_sugar_isom)",5,"GLY A  96;ALA A 118;LEU A  61;VAL A 180;LEU A 186","None;None;CME A 147 ( 4.9A);None;None","1.07A","5lw1H-1upiA:undetectable","5lw1H-1upiA:19.00"],["5LW1_H_ADNH401_1","2b1p","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE 10","PF00069(Pkinase)",7,"GLY A  71;ALA A  91;LEU A 148;MET A 149;ASN A 152;VAL A 196;LEU A 206","AIZ A 501 ( 4.0A);AIZ A 501 (-3.4A);AIZ A 501 ( 4.7A);None;AIZ A 501 (-3.6A);None;AIZ A 501 (-4.0A)","0.91A","5lw1H-2b1pA:43.9","5lw1H-2b1pA:93.65"],["5LW1_H_ADNH401_1","2b1p","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE 10","PF00069(Pkinase)",7,"VAL A  78;ALA A  91;LEU A 148;MET A 149;ASN A 152;VAL A 196;LEU A 206","AIZ A 501 ( 4.7A);AIZ A 501 (-3.4A);AIZ A 501 ( 4.7A);None;AIZ A 501 (-3.6A);None;AIZ A 501 (-4.0A)","0.49A","5lw1H-2b1pA:43.9","5lw1H-2b1pA:93.65"],["5LW1_H_ADNH401_1","2b1p","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE 10","PF00069(Pkinase)",7,"VAL A  78;ALA A  91;MET A 146;LEU A 148;ASN A 152;VAL A 196;LEU A 206","AIZ A 501 ( 4.7A);AIZ A 501 (-3.4A);AIZ A 501 (-3.8A);AIZ A 501 ( 4.7A);AIZ A 501 (-3.6A);None;AIZ A 501 (-4.0A)","0.73A","5lw1H-2b1pA:43.9","5lw1H-2b1pA:93.65"],["5LW1_H_ADNH401_1","2f9g","Saccharomyces cerevisiae","MITOGEN-ACTIVATED PROTEIN KINASE FUS3","PF00069(Pkinase)",5,"GLY A  20;VAL A  27;ALA A  40;LEU A  95;MET A  96","ADP A 500 ( 4.1A);ADP A 500 (-4.3A);ADP A 500 ( 3.7A);ADP A 500 ( 4.9A);None","0.54A","5lw1H-2f9gA:24.7","5lw1H-2f9gA:13.06"],["5LW1_H_ADNH401_1","2h34","Mycobacterium tuberculosis","SERINE\/THREONINE-PROTEIN KINASE PKNE","PF00069(Pkinase)",5,"GLY A  23;VAL A  30;ALA A  43;MET A  93;LEU A  95","None","0.70A","5lw1H-2h34A:19.5","5lw1H-2h34A:16.50"],["5LW1_H_ADNH401_1","2hz0","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","PF07714(Pkinase_Tyr)",5,"GLY A 249;VAL A 256;ALA A 269;MET A 318;ASN A 322","None;GIN A 600 ( 4.7A);GIN A 600 (-3.1A);None;None","0.59A","5lw1H-2hz0A:20.6","5lw1H-2hz0A:15.13"],["5LW1_H_ADNH401_1","2ixc","Mycobacterium tuberculosis","DTDP-4-DEHYDRORHAMNOSE 3,5-EPIMERASE RMLC","PF00908(dTDP_sugar_isom)",5,"GLY A  96;ALA A 118;LEU A  61;VAL A 180;LEU A 186","None","0.91A","5lw1H-2ixcA:undetectable","5lw1H-2ixcA:18.91"],["5LW1_H_ADNH401_1","2j0j","Gallus gallus","FOCAL ADHESION KINASE 1","PF00373(FERM_M);PF07714(Pkinase_Tyr)",5,"GLY A 429;VAL A 436;ALA A 452;MET A 499;LEU A 501","4ST A1687 (-3.1A);4ST A1687 ( 4.8A);4ST A1687 (-3.3A);4ST A1687 ( 3.9A);4ST A1687 (-4.3A)","0.43A","5lw1H-2j0jA:20.5","5lw1H-2j0jA:8.72"],["5LW1_H_ADNH401_1","2jc6","Homo sapiens","CALCIUM\/CALMODULIN-DEPENDENT PROTEIN KINASE TYPE 1D","PF00069(Pkinase)",5,"GLY A  30;VAL A  37;ALA A  50;MET A  98;LEU A 100","QPP A1314 ( 3.7A);QPP A1314 ( 4.6A);QPP A1314 ( 3.7A);QPP A1314 ( 4.1A);QPP A1314 (-4.5A)","0.70A","5lw1H-2jc6A:19.7","5lw1H-2jc6A:13.17"],["5LW1_H_ADNH401_1","2jkm","Gallus gallus","FOCAL ADHESION KINASE 1","PF07714(Pkinase_Tyr)",5,"GLY A 429;VAL A 436;ALA A 452;MET A 499;LEU A 501","BII A1687 ( 3.8A);BII A1687 ( 4.7A);BII A1687 (-3.5A);BII A1687 (-4.1A);BII A1687 (-4.4A)","0.59A","5lw1H-2jkmA:20.2","5lw1H-2jkmA:12.68"],["5LW1_H_ADNH401_1","2phk","Oryctolagus cuniculus","PHOSPHORYLASE KINASE","PF00069(Pkinase)",5,"GLY A  26;VAL A  33;ALA A  46;LEU A 105;MET A 106","ATP A 381 (-3.5A);ATP A 381 (-4.1A);ATP A 381 (-3.5A);None;None","0.48A","5lw1H-2phkA:23.3","5lw1H-2phkA:13.43"],["5LW1_H_ADNH401_1","2qkw","Solanum pimpinellifolium","PROTEIN KINASE","PF07714(Pkinase_Tyr)",5,"GLY B  48;VAL B  55;ALA B  67;MET B 117;ASN B 121","None","0.40A","5lw1H-2qkwB:20.9","5lw1H-2qkwB:13.56"],["5LW1_H_ADNH401_1","2r4b","Homo sapiens","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4","PF07714(Pkinase_Tyr)",5,"GLY A 725;VAL A 732;ALA A 749;LEU A 798;MET A 799","None;GW7 A   1 ( 4.8A);GW7 A   1 (-3.3A);GW7 A   1 (-4.5A);None","0.61A","5lw1H-2r4bA:19.9","5lw1H-2r4bA:13.31"],["5LW1_H_ADNH401_1","2v55","Homo sapiens","RHO-ASSOCIATED PROTEIN KINASE 1","PF00069(Pkinase)",5,"GLY A  83;VAL A  90;ALA A 103;MET A 153;MET A 156","ANP A1480 ( 4.3A);None;ANP A1480 ( 3.9A);ANP A1480 (-4.1A);None","0.52A","5lw1H-2v55A:22.7","5lw1H-2v55A:9.85"],["5LW1_H_ADNH401_1","2w3y","Pectobacterium carotovorum","VIRULENCE FACTOR","no annotation",5,"GLY A  35;VAL A  42;ALA A 171;ASN A  79;VAL A  78","None","1.03A","5lw1H-2w3yA:undetectable","5lw1H-2w3yA:13.78"],["5LW1_H_ADNH401_1","2xk9","Homo sapiens","CHECKPOINT KINASE 2","PF00069(Pkinase)",5,"GLY A 227;VAL A 234;ALA A 247;LEU A 303;MET A 304","XK9 A1511 ( 4.5A);XK9 A1511 (-4.8A);XK9 A1511 ( 4.1A);XK9 A1511 (-4.1A);None","0.53A","5lw1H-2xk9A:14.9","5lw1H-2xk9A:14.78"],["5LW1_H_ADNH401_1","2y7j","Homo sapiens","PHOSPHORYLASE B KINASE GAMMA CATALYTIC CHAIN, TESTIS\/LIVER ISOFORM","PF00069(Pkinase)",5,"GLY A  31;VAL A  38;ALA A  51;LEU A 109;MET A 110","B49 A1294 (-4.0A);None;B49 A1294 (-3.2A);B49 A1294 ( 4.7A);None","0.43A","5lw1H-2y7jA:12.5","5lw1H-2y7jA:13.89"],["5LW1_H_ADNH401_1","2yfk","Enterococcus faecalis","ASPARTATE\/ORNITHINE CARBAMOYLTRANSFERASE","PF00185(OTCace);PF02729(OTCace_N)",5,"GLY A  63;ALA A  81;MET A 371;VAL A 157;LEU A 159","None","1.00A","5lw1H-2yfkA:undetectable","5lw1H-2yfkA:10.02"],["5LW1_H_ADNH401_1","2z8c","Homo sapiens","INSULIN RECEPTOR","PF07714(Pkinase_Tyr)",6,"GLY A1003;VAL A1010;ALA A1028;MET A1076;LEU A1078;MET A1079","S91 A   1 ( 3.9A);S91 A   1 ( 4.9A);S91 A   1 (-3.2A);S91 A   1 ( 4.9A);S91 A   1 (-4.7A);None","0.62A","5lw1H-2z8cA:22.6","5lw1H-2z8cA:16.81"],["5LW1_H_ADNH401_1","3coi","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE 13","PF00069(Pkinase)",6,"GLY A  32;VAL A  39;ALA A  52;MET A 107;MET A 110;LEU A 167","None","0.78A","5lw1H-3coiA:36.1","5lw1H-3coiA:11.93"],["5LW1_H_ADNH401_1","3e7o","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE 9","PF00069(Pkinase)",8,"GLY A  33;VAL A  40;ALA A  53;MET A 108;LEU A 110;MET A 111;ASN A 114;VAL A 158","35F A   1 ( 4.8A);35F A   1 ( 4.8A);35F A   1 (-3.6A);35F A   1 ( 3.9A);35F A   1 (-4.5A);None;None;None","0.73A","5lw1H-3e7oA:43.5","5lw1H-3e7oA:70.51"],["5LW1_H_ADNH401_1","3e7o","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE 9","PF00069(Pkinase)",8,"GLY A  33;VAL A  40;ALA A  53;MET A 108;LEU A 110;MET A 111;VAL A 158;LEU A 168","35F A   1 ( 4.8A);35F A   1 ( 4.8A);35F A   1 (-3.6A);35F A   1 ( 3.9A);35F A   1 (-4.5A);None;None;35F A   1 (-4.5A)","0.48A","5lw1H-3e7oA:43.5","5lw1H-3e7oA:70.51"],["5LW1_H_ADNH401_1","3fme","Homo sapiens","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6","PF00069(Pkinase)",6,"GLY A  60;VAL A  67;ALA A  80;MET A 129;LEU A 131;MET A 132","STU A   1 (-3.5A);None;STU A   1 (-3.4A);STU A   1 ( 3.8A);STU A   1 (-4.6A);None","0.52A","5lw1H-3fmeA:20.8","5lw1H-3fmeA:12.86"],["5LW1_H_ADNH401_1","3g2f","Homo sapiens","BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-2","PF00069(Pkinase)",5,"GLY A 210;VAL A 217;ALA A 228;MET A 279;LEU A 340","ADP A 900 (-3.4A);ADP A 900 (-4.3A);ADP A 900 (-3.4A);ADP A 900 (-3.6A);ADP A 900 (-4.6A)","0.92A","5lw1H-3g2fA:21.5","5lw1H-3g2fA:15.67"],["5LW1_H_ADNH401_1","3gp0","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE 11","PF00069(Pkinase)",6,"GLY A  31;VAL A  38;ALA A  51;LEU A 108;MET A 109;LEU A 167","None;NIL A   1 ( 4.7A);NIL A   1 (-3.7A);NIL A   1 ( 4.4A);None;NIL A   1 (-4.0A)","0.79A","5lw1H-3gp0A:37.5","5lw1H-3gp0A:14.49"],["5LW1_H_ADNH401_1","3gz7","Bordetella bronchiseptica","PUTATIVE ANTIBIOTIC BIOSYNTHESIS MONOOXYGENASE","PF03992(ABM)",5,"GLY A  21;VAL A  79;LEU A  28;VAL A  38;LEU A  52","None;None;None;None;CIT A  97 (-4.5A)","1.04A","5lw1H-3gz7A:undetectable","5lw1H-3gz7A:21.37"],["5LW1_H_ADNH401_1","3h4i","Actinoplanes teichomyceticus;Amycolatopsis orientalis","GLYCOSYLTRANSFERASE GTFA, GLYCOSYLTRANSFERASE","PF03033(Glyco_transf_28);PF04101(Glyco_tran_28_C)",5,"GLY A 283;VAL A 285;ASN A 277;VAL A 276;LEU A 213","None;None;None;U2F A 547 (-4.0A);None","0.97A","5lw1H-3h4iA:undetectable","5lw1H-3h4iA:10.66"],["5LW1_H_ADNH401_1","3hko","Cryptosporidium parvum","CALCIUM\/CALMODULIN-DEPENDENT PROTEIN KINASE WITH A KINASE DOMAIN AND 2 CALMODULIN-LIKE EF HANDS","PF00069(Pkinase)",5,"GLY A  17;VAL A  24;ALA A  37;LEU A  91;VAL A 194","ANP A 329 (-3.5A);ANP A 329 (-4.4A);ANP A 329 ( 3.7A);ANP A 329 ( 4.7A);None","1.01A","5lw1H-3hkoA:23.4","5lw1H-3hkoA:13.04"],["5LW1_H_ADNH401_1","3hko","Cryptosporidium parvum","CALCIUM\/CALMODULIN-DEPENDENT PROTEIN KINASE WITH A KINASE DOMAIN AND 2 CALMODULIN-LIKE EF HANDS","PF00069(Pkinase)",5,"GLY A  17;VAL A  24;ALA A  37;MET A  89;LEU A  91","ANP A 329 (-3.5A);ANP A 329 (-4.4A);ANP A 329 ( 3.7A);ANP A 329 (-3.7A);ANP A 329 ( 4.7A)","0.32A","5lw1H-3hkoA:23.4","5lw1H-3hkoA:13.04"],["5LW1_H_ADNH401_1","3i6u","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE CHK2","PF00069(Pkinase);PF00498(FHA)",5,"GLY A 227;VAL A 234;ALA A 247;LEU A 303;MET A 304","None","0.75A","5lw1H-3i6uA:21.8","5lw1H-3i6uA:12.65"],["5LW1_H_ADNH401_1","3lj0","Saccharomyces cerevisiae","SERINE\/THREONINE-PROTEIN KINASE\/ENDORIBONUCLEASE IRE1","PF00069(Pkinase);PF06479(Ribonuc_2-5A)",5,"GLY A 681;VAL A 689;ALA A 700;LEU A 747;ASN A 751","ADP A2101 (-3.6A);ADP A2101 (-4.5A);ADP A2101 (-3.5A);None;ADP A2101 (-3.7A)","0.61A","5lw1H-3lj0A:21.3","5lw1H-3lj0A:11.55"],["5LW1_H_ADNH401_1","3lw0","Homo sapiens","INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR","PF07714(Pkinase_Tyr)",6,"GLY A1006;VAL A1013;ALA A1031;MET A1079;LEU A1081;MET A1082","None;None;None;CCX A   1 ( 3.9A);None;None","0.69A","5lw1H-3lw0A:21.7","5lw1H-3lw0A:13.29"],["5LW1_H_ADNH401_1","3lzb","Homo sapiens","EPIDERMAL GROWTH FACTOR RECEPTOR","PF07714(Pkinase_Tyr)",5,"GLY A 695;VAL A 702;ALA A 719;LEU A 768;LEU A 820","ITI A   1 ( 4.8A);ITI A   1 (-4.8A);ITI A   1 (-2.9A);ITI A   1 (-4.8A);ITI A   1 (-4.6A)","0.92A","5lw1H-3lzbA:19.3","5lw1H-3lzbA:12.59"],["5LW1_H_ADNH401_1","3nyo","Homo sapiens","G PROTEIN-COUPLED RECEPTOR KINASE 6","PF00069(Pkinase);PF00615(RGS)",5,"GLY A 193;VAL A 200;ALA A 213;LEU A 265;MET A 266","AMP A 577 ( 3.7A);AMP A 577 (-4.3A);AMP A 577 (-3.4A);AMP A 577 ( 4.9A);None","0.39A","5lw1H-3nyoA:24.7","5lw1H-3nyoA:9.56"],["5LW1_H_ADNH401_1","3o0h","Bartonella henselae","GLUTATHIONE REDUCTASE","PF02852(Pyr_redox_dim);PF07992(Pyr_redox_2)",5,"GLY A 142;VAL A 306;ALA A 302;LEU A 138;LEU A 272","FAD A 500 (-3.2A);None;None;None;FAD A 500 ( 4.5A)","0.99A","5lw1H-3o0hA:undetectable","5lw1H-3o0hA:11.16"],["5LW1_H_ADNH401_1","3oht","Salmo salar","P38A","PF00069(Pkinase)",5,"GLY A  32;VAL A  39;ALA A  52;LEU A 109;LEU A 168","1N1 A1000 (-3.4A);1N1 A1000 (-4.6A);1N1 A1000 (-3.7A);1N1 A1000 (-4.7A);1N1 A1000 ( 3.7A)","0.79A","5lw1H-3ohtA:30.0","5lw1H-3ohtA:35.25"],["5LW1_H_ADNH401_1","3oht","Salmo salar","P38A","PF00069(Pkinase)",5,"GLY A  32;VAL A  39;ALA A  52;LEU A 109;MET A 110","1N1 A1000 (-3.4A);1N1 A1000 (-4.6A);1N1 A1000 (-3.7A);1N1 A1000 (-4.7A);None","0.58A","5lw1H-3ohtA:30.0","5lw1H-3ohtA:35.25"],["5LW1_H_ADNH401_1","3pp0","Homo sapiens","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2","PF07714(Pkinase_Tyr)",5,"GLY A 727;VAL A 734;ALA A 751;LEU A 800;MET A 801","None;03Q A   1 (-4.5A);03Q A   1 (-3.1A);03Q A   1 (-4.6A);None","0.58A","5lw1H-3pp0A:20.7","5lw1H-3pp0A:14.34"],["5LW1_H_ADNH401_1","3rez","Homo sapiens","PLATELET GLYCOPROTEIN IB BETA CHAIN, PLATELET GLYCOPROTEIN IX","PF01462(LRRNT);PF01463(LRRCT)",5,"GLY A  59;ALA A  56;LEU A  32;VAL A  42;LEU A  72","None","0.97A","5lw1H-3rezA:undetectable","5lw1H-3rezA:17.16"],["5LW1_H_ADNH401_1","3she","Homo sapiens","MAP KINASE-ACTIVATED PROTEIN KINASE 3","PF00069(Pkinase)",5,"GLY A  51;VAL A  58;ALA A  71;MET A 118;MET A 121","I85 A 350 (-3.5A);I85 A 350 (-4.9A);I85 A 350 (-3.3A);I85 A 350 ( 3.9A);None","0.51A","5lw1H-3sheA:18.3","5lw1H-3sheA:12.75"],["5LW1_H_ADNH401_1","3vn9","Homo sapiens","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6","PF00069(Pkinase)",6,"GLY A  60;VAL A  67;ALA A  80;MET A 129;LEU A 131;MET A 132","ANK A 401 (-3.4A);ANK A 401 (-4.3A);ANK A 401 (-3.0A);ANK A 401 (-3.7A);None;None","0.60A","5lw1H-3vn9A:21.1","5lw1H-3vn9A:13.82"],["5LW1_H_ADNH401_1","3vn9","Homo sapiens","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6","PF00069(Pkinase)",5,"GLY A  60;VAL A  67;ALA A  80;MET A 129;LEU A 186","ANK A 401 (-3.4A);ANK A 401 (-4.3A);ANK A 401 (-3.0A);ANK A 401 (-3.7A);ANK A 401 ( 4.9A)","1.03A","5lw1H-3vn9A:21.1","5lw1H-3vn9A:13.82"],["5LW1_H_ADNH401_1","3wcz","Bombyx mori","ALDO-KETO REDUCTASE 2E","PF00248(Aldo_ket_red)",5,"GLY A  67;VAL A  41;ALA A  44;VAL A  77;LEU A  82","None","1.05A","5lw1H-3wczA:undetectable","5lw1H-3wczA:14.49"],["5LW1_H_ADNH401_1","3wig","Homo sapiens","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","PF00069(Pkinase)",5,"GLY A  76;VAL A  83;ALA A  96;MET A 144;MET A 147","ANP A 401 ( 3.7A);ANP A 401 ( 4.3A);ANP A 401 (-3.2A);CHU A 403 (-3.8A);None","0.30A","5lw1H-3wigA:21.4","5lw1H-3wigA:15.28"],["5LW1_H_ADNH401_1","4b99","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE 7","PF00069(Pkinase)",5,"GLY A  62;VAL A  69;ALA A  82;LEU A 139;MET A 140","R4L A1394 (-3.6A);R4L A1394 (-4.0A);R4L A1394 ( 3.7A);R4L A1394 ( 4.9A);None","0.42A","5lw1H-4b99A:35.9","5lw1H-4b99A:11.34"],["5LW1_H_ADNH401_1","4btm","Homo sapiens","TAU-TUBULIN KINASE 1","PF00069(Pkinase)",5,"GLY A  65;ALA A  85;LEU A 133;ASN A 137;LEU A 199","F8E A1340 ( 4.3A);F8E A1340 (-3.5A);F8E A1340 (-4.4A);F8E A1340 ( 4.5A);F8E A1340 (-3.8A)","0.87A","5lw1H-4btmA:14.0","5lw1H-4btmA:11.47"],["5LW1_H_ADNH401_1","4btm","Homo sapiens","TAU-TUBULIN KINASE 1","PF00069(Pkinase)",5,"GLY A  65;ALA A  85;MET A 131;LEU A 133;ASN A 137","F8E A1340 ( 4.3A);F8E A1340 (-3.5A);F8E A1340 (-4.2A);F8E A1340 (-4.4A);F8E A1340 ( 4.5A)","0.67A","5lw1H-4btmA:14.0","5lw1H-4btmA:11.47"],["5LW1_H_ADNH401_1","4drr","Rotavirus sp.","OUTER CAPSID PROTEIN VP4","no annotation",5,"GLY A  90;VAL A 106;ALA A 104;VAL A 126;LEU A 128","None","0.86A","5lw1H-4drrA:undetectable","5lw1H-4drrA:17.79"],["5LW1_H_ADNH401_1","4fg8","Homo sapiens","CALCIUM\/CALMODULIN-DEPENDENT PROTEIN KINASE TYPE 1","PF00069(Pkinase)",5,"GLY A  27;VAL A  34;ALA A  47;MET A  95;LEU A  97","ATP A 401 ( 3.7A);ATP A 401 (-4.1A);ATP A 401 (-3.6A);ATP A 401 ( 4.3A);ATP A 401 ( 4.8A)","0.53A","5lw1H-4fg8A:18.0","5lw1H-4fg8A:13.97"],["5LW1_H_ADNH401_1","4fod","Homo sapiens","ALK TYROSINE KINASE RECEPTOR","PF07714(Pkinase_Tyr)",5,"GLY A1123;VAL A1130;ALA A1148;LEU A1198;MET A1199","0UV A1501 ( 4.3A);0UV A1501 (-4.5A);0UV A1501 (-3.4A);0UV A1501 ( 4.8A);None","0.61A","5lw1H-4fodA:20.2","5lw1H-4fodA:16.02"],["5LW1_H_ADNH401_1","4g3f","Mus musculus","NF-KAPPA-BETA-INDUCING KINASE","PF00069(Pkinase)",5,"GLY A 409;VAL A 416;ALA A 429;MET A 471;LEU A 473","0WB A 701 ( 4.4A);0WB A 701 (-4.4A);0WB A 701 (-3.3A);0WB A 701 (-3.9A);0WB A 701 (-4.3A)","0.60A","5lw1H-4g3fA:16.9","5lw1H-4g3fA:13.25"],["5LW1_H_ADNH401_1","4g3f","Mus musculus","NF-KAPPA-BETA-INDUCING KINASE","PF00069(Pkinase)",5,"GLY A 409;VAL A 416;ALA A 429;MET A 471;LEU A 524","0WB A 701 ( 4.4A);0WB A 701 (-4.4A);0WB A 701 (-3.3A);0WB A 701 (-3.9A);0WB A 701 (-4.3A)","0.97A","5lw1H-4g3fA:16.9","5lw1H-4g3fA:13.25"],["5LW1_H_ADNH401_1","4idt","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 14","PF00069(Pkinase)",5,"GLY A 407;VAL A 414;ALA A 427;MET A 469;LEU A 471","T28 A 701 ( 3.6A);T28 A 701 (-4.7A);T28 A 701 (-3.0A);T28 A 701 (-2.6A);T28 A 701 ( 4.8A)","0.51A","5lw1H-4idtA:16.9","5lw1H-4idtA:10.92"],["5LW1_H_ADNH401_1","4j57","Plasmodium falciparum","THIOREDOXIN REDUCTASE 2","PF02852(Pyr_redox_dim);PF07992(Pyr_redox_2)",5,"GLY A 193;VAL A 358;ALA A 354;LEU A 189;LEU A 323","FAD A 601 (-3.3A);None;None;None;FAD A 601 (-4.9A)","0.98A","5lw1H-4j57A:undetectable","5lw1H-4j57A:11.00"],["5LW1_H_ADNH401_1","4jrn","Toxoplasma gondii","RHOPTRY KINASE FAMILY PROTEIN","PF14531(Kinase-like)",5,"GLY A 259;VAL A 266;ALA A 279;MET A 356;LEU A 416","ANP A 601 (-3.4A);ANP A 601 (-4.1A);ANP A 601 ( 3.9A);ANP A 601 (-3.3A);ANP A 601 ( 4.9A)","1.04A","5lw1H-4jrnA:13.7","5lw1H-4jrnA:12.83"],["5LW1_H_ADNH401_1","4mk0","Homo sapiens","BETA-ADRENERGIC RECEPTOR KINASE 1","PF00069(Pkinase);PF00169(PH);PF00615(RGS)",5,"GLY A 198;VAL A 205;ALA A 218;LEU A 273;MET A 274","29X A 702 ( 4.1A);29X A 702 (-4.7A);29X A 702 (-3.1A);29X A 702 (-4.6A);None","0.83A","5lw1H-4mk0A:23.7","5lw1H-4mk0A:8.45"],["5LW1_H_ADNH401_1","4mvf","Plasmodium falciparum","CALCIUM-DEPENDENT PROTEIN KINASE 2","PF00069(Pkinase);PF13499(EF-hand_7)",5,"GLY A  79;VAL A  86;ALA A  99;MET A 146;LEU A 148","STU A 601 (-3.6A);STU A 601 (-4.8A);STU A 601 (-3.3A);STU A 601 ( 4.3A);STU A 601 (-4.3A)","0.53A","5lw1H-4mvfA:19.8","5lw1H-4mvfA:9.49"],["5LW1_H_ADNH401_1","4nfn","Homo sapiens","TAU-TUBULIN KINASE 1","PF00069(Pkinase)",5,"ALA A  61;MET A 107;LEU A 109;ASN A 113;LEU A 175","2KC A 401 (-2.7A);2KC A 401 (-4.1A);2KC A 401 ( 4.7A);None;2KC A 401 ( 3.9A)","0.89A","5lw1H-4nfnA:19.1","5lw1H-4nfnA:11.73"],["5LW1_H_ADNH401_1","4nfn","Homo sapiens","TAU-TUBULIN KINASE 1","PF00069(Pkinase)",5,"GLY A  41;ALA A  61;MET A 107;LEU A 109;LEU A 175","2KC A 401 ( 3.2A);2KC A 401 (-2.7A);2KC A 401 (-4.1A);2KC A 401 ( 4.7A);2KC A 401 ( 3.9A)","0.99A","5lw1H-4nfnA:19.1","5lw1H-4nfnA:11.73"],["5LW1_H_ADNH401_1","4pwn","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE WNK1","PF00069(Pkinase)",5,"GLY A 228;VAL A 235;ALA A 248;LEU A 303;MET A 304","None","0.53A","5lw1H-4pwnA:20.1","5lw1H-4pwnA:14.44"],["5LW1_H_ADNH401_1","4q6l","Salmonella enterica","PENICILLIN-BINDING PROTEIN ACTIVATOR LPOB","PF13036(LpoB)",5,"VAL A  87;MET A 191;LEU A 193;VAL A 104;LEU A 124","None","1.06A","5lw1H-4q6lA:undetectable","5lw1H-4q6lA:23.48"],["5LW1_H_ADNH401_1","4qi3","Crassicarpon hotsonii","CELLOBIOSE DEHYDROGENASE","PF16010(CDH-cyt)",5,"GLY A 149;ALA A 144;ASN A  18;VAL A  37;LEU A  39"," MG A 407 (-3.8A);None;None;None;None","1.01A","5lw1H-4qi3A:undetectable","5lw1H-4qi3A:22.05"],["5LW1_H_ADNH401_1","4qny","Leishmania donovani","MITOGEN ACTIVATED PROTEIN KINASE, PUTATIVE","PF00069(Pkinase)",5,"GLY A  28;VAL A  35;ALA A  49;MET A 104;MET A 107","ANP A 402 ( 3.7A);ANP A 402 (-4.3A);ANP A 402 (-3.3A);ANP A 402 (-4.4A);None","0.48A","5lw1H-4qnyA:35.3","5lw1H-4qnyA:14.04"],["5LW1_H_ADNH401_1","4qtb","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE 3","PF00069(Pkinase)",5,"GLY A  49;VAL A  56;ALA A  69;LEU A 124;MET A 125","None;None;38Z A 418 (-3.4A);38Z A 418 ( 4.8A);None","0.41A","5lw1H-4qtbA:37.8","5lw1H-4qtbA:10.46"],["5LW1_H_ADNH401_1","4tyh","Mus musculus","MITOGEN-ACTIVATED PROTEIN KINASE 14","PF00069(Pkinase)",5,"GLY B  31;ALA B  51;LEU B 108;MET B 109;LEU B 167","None;39G B 401 (-3.5A);39G B 401 ( 4.9A);39G B 401 (-4.8A);39G B 401 (-3.6A)","0.80A","5lw1H-4tyhB:15.5","5lw1H-4tyhB:11.21"],["5LW1_H_ADNH401_1","4tyh","Mus musculus","MITOGEN-ACTIVATED PROTEIN KINASE 14","PF00069(Pkinase)",5,"GLY B  31;VAL B  38;ALA B  51;LEU B 108;MET B 109","None;None;39G B 401 (-3.5A);39G B 401 ( 4.9A);39G B 401 (-4.8A)","0.77A","5lw1H-4tyhB:15.5","5lw1H-4tyhB:11.21"],["5LW1_H_ADNH401_1","4u6d","Zobellia galactanivorans","CONSERVED HYPOTHETICAL PERIPLASMIC PROTEIN","no annotation",5,"GLY A 283;VAL A 299;ALA A 297;LEU A 288;VAL A 279","None","1.08A","5lw1H-4u6dA:undetectable","5lw1H-4u6dA:12.40"],["5LW1_H_ADNH401_1","4wbo","Bos taurus","RHODOPSIN KINASE","PF00069(Pkinase);PF00615(RGS)",5,"GLY A 194;VAL A 201;ALA A 214;MET A 264;MET A 267","None;None;ANW A 601 (-3.4A);ANW A 601 (-3.2A);None","0.45A","5lw1H-4wboA:18.3","5lw1H-4wboA:10.70"],["5LW1_H_ADNH401_1","4xrl","Rattus norvegicus","MITOGEN-ACTIVATED PROTEIN KINASE 1","PF00069(Pkinase)",5,"GLY A  30;VAL A  37;ALA A  50;LEU A 105;MET A 106","None;None;42A A 402 (-3.2A);42A A 402 ( 4.9A);None","0.58A","5lw1H-4xrlA:37.2","5lw1H-4xrlA:10.94"],["5LW1_H_ADNH401_1","5awm","Drosophila melanogaster","STRESS-ACTIVATED PROTEIN KINASE JNK","PF00069(Pkinase)",7,"GLY A  31;ALA A  51;MET A 106;LEU A 108;MET A 109;VAL A 156;LEU A 166","ANP A 401 (-3.3A);ANP A 401 (-3.5A);ANP A 401 (-3.8A);ANP A 401 ( 4.8A);None;None;ANP A 401 ( 4.5A)","0.71A","5lw1H-5awmA:44.0","5lw1H-5awmA:64.44"],["5LW1_H_ADNH401_1","5awm","Drosophila melanogaster","STRESS-ACTIVATED PROTEIN KINASE JNK","PF00069(Pkinase)",8,"VAL A  38;ALA A  51;MET A 106;LEU A 108;MET A 109;ASN A 112;VAL A 156;LEU A 166","ANP A 401 (-4.5A);ANP A 401 (-3.5A);ANP A 401 (-3.8A);ANP A 401 ( 4.8A);None;ANP A 401 (-3.9A);None;ANP A 401 ( 4.5A)","0.45A","5lw1H-5awmA:44.0","5lw1H-5awmA:64.44"],["5LW1_H_ADNH401_1","5b4s","Mitsuaria chitosanitabida","CHITOSANASE","PF13647(Glyco_hydro_80)",5,"GLY A 112;VAL A 115;ALA A 153;LEU A 154;LEU A  98","None","1.08A","5lw1H-5b4sA:undetectable","5lw1H-5b4sA:15.36"],["5LW1_H_ADNH401_1","5dbx","Mus musculus","STE20\/SPS1-RELATED PROLINE-ALANINE-RICH PROTEIN KINASE","PF00069(Pkinase)",5,"GLY A  82;VAL A  89;ALA A 102;MET A 150;LEU A 152","ANP A 401 ( 3.9A);ANP A 401 (-4.0A);ANP A 401 ( 4.0A);ANP A 401 (-4.0A);None","0.42A","5lw1H-5dbxA:18.8","5lw1H-5dbxA:14.15"],["5LW1_H_ADNH401_1","5j9z","Homo sapiens","EPIDERMAL GROWTH FACTOR RECEPTOR","PF07714(Pkinase_Tyr)",5,"GLY A 719;VAL A 726;ALA A 743;LEU A 792;MET A 793","6HJ A1101 ( 4.2A);6HJ A1101 ( 4.7A);6HJ A1101 (-3.1A);6HJ A1101 ( 4.9A);None","0.66A","5lw1H-5j9zA:20.2","5lw1H-5j9zA:12.42"],["5LW1_H_ADNH401_1","5j9z","Homo sapiens","EPIDERMAL GROWTH FACTOR RECEPTOR","PF07714(Pkinase_Tyr)",5,"GLY A 719;VAL A 726;ALA A 743;MET A 790;LEU A 792","6HJ A1101 ( 4.2A);6HJ A1101 ( 4.7A);6HJ A1101 (-3.1A);6HJ A1101 (-3.4A);6HJ A1101 ( 4.9A)","0.77A","5lw1H-5j9zA:20.2","5lw1H-5j9zA:12.42"],["5LW1_H_ADNH401_1","5jzn","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE DCLK1","PF00069(Pkinase)",5,"GLY A 397;VAL A 404;ALA A 417;MET A 465;LEU A 467","GUI A 701 ( 3.8A);GUI A 701 (-4.4A);GUI A 701 ( 3.9A);GUI A 701 ( 4.1A);GUI A 701 ( 4.7A)","0.66A","5lw1H-5jznA:19.6","5lw1H-5jznA:14.13"],["5LW1_H_ADNH401_1","5lxd","Homo sapiens","DUAL SPECIFICITY TYROSINE-PHOSPHORYLATION-REGULATED KINASE 2","PF00069(Pkinase)",5,"GLY A 156;VAL A 163;ALA A 176;LEU A 230;ASN A 234","7A7 A 501 (-3.2A);7A7 A 501 (-4.4A);7A7 A 501 (-3.5A);None;None","0.74A","5lw1H-5lxdA:22.3","5lw1H-5lxdA:13.64"],["5LW1_H_ADNH401_1","5o2c","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE WNK3","PF00069(Pkinase);PF12202(OSR1_C)",5,"GLY A 154;VAL A 161;ALA A 174;LEU A 229;MET A 230","None;None;GOL A 604 ( 3.8A);GOL A 604 ( 4.8A);None","0.42A","5lw1H-5o2cA:21.2","5lw1H-5o2cA:11.35"],["5LW1_H_ADNH401_1","5tur","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE PIM-1","no annotation",5,"GLY A  45;VAL A  52;ALA A  65;VAL A 126;LEU A 174","None;7LK A 401 (-4.9A);7LK A 401 (-3.3A);None;7LK A 401 (-4.8A)","1.02A","5lw1H-5turA:21.9","5lw1H-5turA:13.20"],["5LW1_H_ADNH401_1","5u7q","Homo sapiens","RHO-ASSOCIATED PROTEIN KINASE 2","PF00069(Pkinase)",5,"GLY A  99;VAL A 106;ALA A 119;MET A 169;MET A 172","None","0.42A","5lw1H-5u7qA:23.5","5lw1H-5u7qA:10.53"],["5LW1_H_ADNH401_1","5uuu","Homo sapiens","BETA-ADRENERGIC RECEPTOR KINASE 1","PF00069(Pkinase);PF00615(RGS)",5,"GLY A 198;VAL A 205;ALA A 218;LEU A 273;MET A 274","QRW A 601 ( 4.5A);QRW A 601 (-4.7A);QRW A 601 (-3.4A);None;MES A 604 (-3.9A)","0.69A","5lw1H-5uuuA:23.4","5lw1H-5uuuA:10.42"],["5LW1_H_ADNH401_1","5wnm","Mus musculus","RECEPTOR-INTERACTING SERINE\/THREONINE-PROTEIN KINASE 4","no annotation",5,"GLY A  29;VAL A  36;ALA A  49;MET A  96;MET A  99","VX6 A 402 ( 4.2A);VX6 A 402 (-4.6A);VX6 A 402 (-3.2A);VX6 A 402 (-3.7A);None","0.55A","5lw1H-5wnmA:21.7","5lw1H-5wnmA:21.28"],["5LW1_H_ADNH401_1","5x1y","Lysinibacillus sphaericus","MERCURIC REDUCTASE","no annotation",5,"GLY B 220;VAL B 388;ALA B 384;LEU B 216;LEU B 354","FAD B 601 (-3.1A);None;None;None;FAD B 601 (-4.6A)","0.97A","5lw1H-5x1yB:undetectable","5lw1H-5x1yB:11.47"],["5LW1_H_ADNH401_1","6ao5","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE 3","no annotation",5,"GLY A  34;VAL A  41;ALA A  54;MET A  99;LEU A 153","ANP A 501 ( 3.9A);ANP A 501 (-4.4A);ANP A 501 ( 3.7A);ANP A 501 (-2.5A);ANP A 501 (-4.6A)","1.08A","5lw1H-6ao5A:19.8","5lw1H-6ao5A:11.93"],["5LW1_H_ADNH401_1","6b4o","Enterococcus faecalis","GLUTATHIONE REDUCTASE","no annotation",5,"GLY A 139;VAL A 303;ALA A 299;LEU A 135;LEU A 269","FAD A 501 (-3.3A);None;None;None;None","0.97A","5lw1H-6b4oA:undetectable","5lw1H-6b4oA:12.85"],["5LW1_H_ADNH401_1","6b7p","Legionella pneumophila","SDED","no annotation",5,"GLY A 270;VAL A 269;MET A 230;ASN A 273;VAL A 274","None","1.05A","5lw1H-6b7pA:undetectable","5lw1H-6b7pA:23.53"],["5LW1_H_ADNH401_1","6c7y","Homo sapiens","TYROSINE-PROTEIN KINASE JAK1","no annotation",5,"GLY A 882;VAL A 889;ALA A 906;MET A 956;LEU A1010","ADP A1201 (-3.5A);ADP A1201 (-4.3A);ADP A1201 (-3.4A);ADP A1201 (-4.2A);ADP A1201 (-4.5A)","0.96A","5lw1H-6c7yA:21.0","5lw1H-6c7yA:22.09"],["5LW1_H_ADNH401_1","6cz4","Homo sapiens","PROTEIN-TYROSINE KINASE 6","no annotation",5,"GLY A 198;VAL A 205;ALA A 217;LEU A 266;MET A 267","FKY A9001 ( 4.0A);FKY A9001 ( 4.6A);FKY A9001 (-3.3A);FKY A9001 (-4.4A);None","0.37A","5lw1H-6cz4A:19.9","5lw1H-6cz4A:24.49"],["5LW1_H_ADNH401_1","6fyl","Homo sapiens","DUAL SPECIFICITY PROTEIN KINASE CLK2","no annotation",5,"GLY A 170;VAL A 177;ALA A 191;LEU A 245;LEU A 297","3NG A 501 (-3.5A);3NG A 501 ( 4.4A);3NG A 501 (-3.3A);3NG A 501 ( 4.7A);None","1.07A","5lw1H-6fylA:17.4","5lw1H-6fylA:undetectable"]]